Neuronetics stock kpis
Want to see STIM full AI Analyst Report?
Revenue by Segment
In Q1 2026, Neuronetics reported revenue by segment of $372.00K (Other), $3.20M (Neurostar Advanced Therapy System), $9.12M (Treatment Sessions) and $21.53M (Clinic).
Breaks down revenue into device sales, recurring consumables and service contracts, leasing and training. Reveals whether growth is driven by one-time equipment sales or by recurring streams that support steadier margins and cash flow; heavy reliance on device sales can mean lumpier results and greater sensitivity to capital spending cycles.
Revenue growth is now driven almost entirely by the newly reported Clinic line after the Greenbrook integration—a meaningful inflection that lifted top‑line but compressed gross margins—while NeuroStar device revenue and treatment-session trends show softness, signaling limited organic recovery. Management’s shift to buy‑and‑bill for SPRAVATO and operational savings aim to reach cash‑flow positivity, but investors should treat recent revenue gains as acquisition‑driven mix change rather than a durable rebound in core NeuroStar demand.
STIM Revenue by Segment
| Period | Other | Neurostar Advanced Therapy System | Treatment Sessions | Clinic |
|---|---|---|---|---|
| Q1 2026Mar 31, 2026 | $372.00K | $3.20M | $9.12M | $21.53M |
| Q4 2025Dec 31, 2025 | $363.00K | $4.42M | $12.39M | $23.49M |
| Q3 2025Sep 30, 2025 | $389.00K | $3.51M | $10.54M | $21.81M |
| Q2 2025Jun 30, 2025 | $375.00K | $3.48M | $10.77M | $23.02M |
| Q1 2025Mar 31, 2025 | $366.00K | $2.85M | $9.61M | $18.66M |
| Q4 2024Dec 31, 2024 | $490.00K | $3.85M | $12.86M | $4.45M |
| Q3 2024Sep 30, 2024 | $488.00K | $4.11M | $13.33M | $0.00 |
| Q2 2024Jun 30, 2024 | $470.00K | $4.00M | $11.66M | $0.00 |
| Q1 2024Mar 31, 2024 | $495.00K | $3.31M | $12.99M | $0.00 |
| Q4 2023Dec 31, 2023 | $470.00K | $4.52M | $14.88M | $0.00 |
| Q3 2023Sep 30, 2023 | $554.00K | $3.60M | $13.06M | $0.00 |
| Q2 2023Jun 30, 2023 | $486.00K | $4.49M | $12.31M | $0.00 |
| Q1 2023Mar 31, 2023 | $471.00K | $3.85M | $10.64M | $0.00 |
| Q4 2022Dec 31, 2022 | $447.00K | $4.62M | $12.45M | $0.00 |
| Q3 2022Sep 30, 2022 | $446.00K | $3.93M | $11.86M | $0.00 |
| Q2 2022Jun 30, 2022 | $455.00K | $4.38M | $11.29M | $0.00 |
| Q1 2022Mar 31, 2022 | $406.00K | $3.64M | $9.47M | $0.00 |
| Q4 2021Dec 31, 2021 | $496.00K | $2.81M | $11.24M | $0.00 |
| Q3 2021Sep 30, 2021 | $409.00K | $2.61M | $10.26M | $0.00 |
| Q2 2021Jun 30, 2021 | $431.00K | $2.58M | $10.80M | $0.00 |
| Q1 2021Mar 31, 2021 | $418.00K | $1.75M | $9.63M | $0.00 |
| Q4 2020Dec 31, 2020 | $397.00K | $3.62M | $11.03M | $0.00 |
| Q3 2020Sep 30, 2020 | $405.00K | $2.54M | $9.08M | $0.00 |
| Q2 2020Jun 30, 2020 | $382.00K | $2.34M | $6.55M | $0.00 |
| Q1 2020Mar 31, 2020 | $390.00K | $2.59M | $8.19M | $0.00 |

